Surufatinib and Toripalimab Combined With Chemotherapy for Second-line Treatment of Advanced RAS/BRAF Mutant and Microsatellite Stable Colorectal Cancer
Latest Information Update: 19 Jul 2023
At a glance
- Drugs Surufatinib (Primary) ; Toripalimab (Primary) ; Irinotecan; Oxaliplatin
- Indications Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- 14 Jul 2023 Planned End Date changed from 1 Jan 2025 to 1 Jun 2025.
- 14 Jul 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jun 2025.
- 08 Feb 2021 Status changed from not yet recruiting to recruiting.